Heterologous expression of synthetic chicken IFN-γ in transgenic tobacco plants

Wu, Yongjun; Zhao, Degang; Song, Li; Xu, Weina

doi:10.2478/s11756-009-0203-7

Cited by 15 publications

(12 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although, at the beginning of IFN therapy bovine IFN-c was used even to treat human beings, nowadays physicians and veterinary surgeons prefer to use the IFNs specific for human or animal species (Chen et al 2004;Wu et al 2009;Jalali et al 2010). Perhaps it explains our results demonstrating relatively weak effect of the plant-made bovine IFN-c on laboratory mice IgG (Fig.…”

Section: Discussionmentioning

confidence: 99%

“…This restriction has been removed with the advent of genetically engineered organisms to produce recombinant proteins. Recombinant human IFNs have been produced in bacteria and yeast, in insect and mammalian cell cultures, and in several plant species (Wu et al 2002(Wu et al , 2008(Wu et al , 2009Chen et al 2004;Sharma 2009;Jalali et al 2010;Sirko et al 2011).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Production of bovine interferon-gamma in transgenic tobacco plants

Burlakovskiy

Savel'eva

Yemelyanov

et al. 2015

Plant Cell Tiss Organ Cult

View full text Add to dashboard Cite

The inbreed line of Nicotiana tabacum L. plants harboring a heterologous gene of bovine interferongamma sIFNG under the control of constitutive 35S CaMV promoter was created by Agrobacterium-mediated genetic transformation. The transformation of leaf discs yielded six independent transgenic plants (T 0 generation). All six transformants demonstrated presence of sIFNG insertion and had a normal phenotype. Self-pollination of T 0 plants provided six transgenic families. All families but one inherited sIFNG insertion in T 1 progeny and were used for subsequent selection. Offsprings of selfing were tested for the presence and expression of sIFNG gene and the synthesis of bovine interferon-gamma protein. We identified homozygous sIFNG plant of Inter311.2 family in T 1 generation, which was laid the founder of the inbreed line of transgenic sIFNG tobacco. The line demonstrated stable inheritance and expression of the transgene insertion and presence of a heterologous interferon-gamma protein in the plant tissue up to the fourth generation of transgenic plants tested. Antiviral and immunomodulatory activities of plantproduced interferon-gamma upon bovine cell cultures and laboratory animals (mice) were observed. Created tobacco plants may be used as the bioreactors for production of bovine interferon-gamma for veterinary.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Production of bovine interferon-gamma in transgenic tobacco plants

Burlakovskiy

Savel'eva

Yemelyanov

et al. 2015

Plant Cell Tiss Organ Cult

View full text Add to dashboard Cite

show abstract

“…Each system has its advantages and limitations and the method of choice is largely depending on what kind of fish vaccines are to be expressed, as briefly described in Table 2. To date, both food and non-food crops (especially tobacco plant) have been used for the development of a number of animal vaccines, such as a poultry vaccine against Newcastle disease (Hahn et al 2007; Yang et al 2007; Li et al 2007; Gómez et al2009; Van Eck and Keen 2009; Wu et al 2009: for reviews see Floss et al 2007 and He et al 2008), rabies (Ashraf et al 2005; Loza-Rubio et al 2008; Roy et al 2010; Loza-Rubio et al 2012), Porcine reproductive and respiratory syndrome virus (PRRSV) and Porcine post-weaning diarrhea in piglets (Chen and Liu 2011; Kolotilin et al 2012). The vaccine against Newcastle disease was the first plant-made animal vaccine receiving regulatory approval from the US Department of Agriculture (USDA) Center for Veterinary Biologics in 2006 (www.thepoultrysite.com/poultrynews/8949/usda-issues-license-for-plant-cell-producednewcastle-disease-vaccine-for-chickens; Joensuu et al 2008).…”

Section: Exploitation Of Plant Genetic Engineering For Low Cost Produmentioning

confidence: 99%

How can plant genetic engineering contribute to cost-effective fish vaccine development for promoting sustainable aquaculture?

et al. 2013

View full text Add to dashboard Cite

Aquaculture, the fastest growing food-producing sector, now accounts for nearly 50 % of the world’s food fish (FAO in The state of world fisheries and aquaculture. FAO, Rome, 2010). The global aquaculture production of food fish reached 62.7 million tonnes in 2011 and is continuously increasing with an estimated production of food fish of 66.5 million tonnes in 2012 (a 9.4 % increase in 1 year, FAO, www.fao.org/fishery/topic/16140). Aquaculture is not only important for sustainable protein-based food fish production but also for the aquaculture industry and economy worldwide. Disease prevention is the key issue to maintain a sustainable development of aquaculture. Widespread use of antibiotics in aquaculture has led to the development of antibiotic-resistant bacteria and the accumulation of antibiotics in the environment, resulting in water and soil pollution. Thus, vaccination is the most effective and environmentally-friendly approach to combat diseases in aquaculture to manage fish health. Furthermore, when compared to >760 vaccines against human diseases, there are only about 30 fish vaccines commercially available, suggesting the urgent need for development and cost-effective production of fish vaccines for managing fish health, especially in the fast growing fish farming in Asia where profit is minimal and therefore given high priority. Plant genetic engineering has made significant contributions to production of biotech crops for food, feed, valuable recombinant proteins etc. in the past three decades. The use of plants for vaccine production offers several advantages such as low cost, safety and easy scaling up. To date a large number of plant-derived vaccines, antibodies and therapeutic proteins have been produced for human health, of which a few have been made commercially available. However, the development of animal vaccines in plants, especially fish vaccines by genetic engineering, has not yet been addressed. Therefore, there is a need to exploit plant biotechnology for cost effective fish vaccine development in plants, in particular, edible crops for oral fish vaccines. This review provides insight into (1) the current status of fish vaccine and vaccination in aquaculture, (2) plant biotechnology and edible crops for fish vaccines for oral administration, (3) regulatory constraints and (4) conclusions and future perspectives.

show abstract

“…Production of the Hu-IFN-γ from yeast and mammalian cells is expensive, which can limit the use of this drug in developing countries. Plants are known to act as bioreactors that might be a successful and economical means for the production of recombinant proteins (13,22). Plants as a host system have several advantages over industrial systems, such as higher biological activity, high gene expression, high production of recombinant proteins, greater stability, safety against human-animal diseases for instance HCV, HIV etc (14,21).…”

Section: Introductionmentioning

confidence: 99%